NAP1L1 interacts with hepatoma-derived growth factor to recruit c-Jun inducing breast cancer growth

Liu, Shu; Zhang, Yewei; Cui, Shien; Song, Dajiang; Li, Bo; Chen, Qian; Yao, Guangyu; Gong, Bin

doi:10.1186/s12935-021-02301-3

Cited by 9 publications

(7 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…High MECOM expression is an independent factor, which indicates a poor prognosis in HCC patients. Nucleosome Protein Assembly 1 Like 1 (NAP1L1) is associated with the pathogenesis of many cancers, such as breast cancer, colorectal cancer, nasopharyngeal carcinoma, ovarian cancer, lung cancer, glioma, and hepatocellular carcinoma [19][20][21][22][23][24][25]. An elevated NAP1L1 protein level is a signi cantly unfavorable outcome for HCC patients.…”

Section: Discussionmentioning

confidence: 99%

Identification of a chromatin regulator signature and potential candidate drugs for hepatocellular carcinoma

Mao

Tang

2023

Preprint

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is a cancerous tumor that has an unfavorable prognosis. The involvement of chromatin regulators (CRs) in the development of cancer is now supported by a growing body of research. Therefore, we aimed at investigate the function and prognostic importance of CRs in HCC patients. From the prior outstanding research, chromatin regulators (CRs) were obtained. The mRNA expression and clinical data were acquired from the TCGA database. Utilizing Cox regression analysis and least absolute shrinkage and selection operator (LASSO) regression analysis, a risk model for predicting the outcome of HCC was created using the prognostic gene. The Kaplan-Meier analysis was conducted in order to compare the prognosis between high-risk and low-risk groups. We also looked into the differences in drug sensitivity between high-risk and low-risk groups. To estimate prospective small molecule drug therapy, the CMAP dataset was employed. A 13 CRs-based model for predicting the prognosis of HCC patients was effectively built and verified. Furthermore, we discovered that the 13 CRs-based model was a standalone prognostic factor. Functional analysis suggested that the majority of the signaling pathways involved in cancer were enriched in CRs. The immune checkpoint and immune cell infiltration were also associated with the CR-based model. Several medications, including Docetaxel, DMOG, Dasatinib, Axitinib, and Vorinostat, were more sensitive for patients in the high-risk category. Eight small molecule drugs could be beneficial in the treatment of people with HCC. As a result, our research offered novel perspectives into the function of CRs in HCC. We identified a trustworthy prognostic biomarker for the survival of HCC patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Identification of a chromatin regulator signature and potential candidate drugs for hepatocellular carcinoma

Mao

Tang

2023

Preprint

View full text Add to dashboard Cite

show abstract

“…NAP1L1 is a critical member of the Nucleosome Assembly Protein (NAP) family and has been widely portrayed in various tumor progressions ( Aydin et al, 2020 ; Chen et al, 2021 ; Liu X. et al, 2021 ). The high expression of NAP1L1 has existed in the heap of human neoplasms covering nasopharyngeal carcinoma ( Liu S. et al, 2021 ), lung adenocarcinoma ( Nagashio et al, 2020 ), glioblastoma ( Zottel et al, 2020 ), colon cancer ( Aydin et al, 2020 ), colorectal cancer ( Queiroz et al, 2020 ), breast cancer ( Liu S. et al, 2021 ), small-intestinal carcinoid ( Kidd et al, 2006 ), and pancreatic neuroendocrine neoplasm ( Schimmack et al, 2014 ). In addition, previous studies have confirmed the high expression was relevant to the worse survival in nasopharyngeal carcinoma ( Liu X. et al, 2021 ), lung adenocarcinoma ( Nagashio et al, 2020 ), colon cancer ( Aydin et al, 2020 ), and breast cancer ( Liu S. et al, 2021 ).…”

Section: Discussionmentioning

confidence: 99%

NAP1L1 Functions as a Novel Prognostic Biomarker Associated With Macrophages and Promotes Tumor Progression by Influencing the Wnt/β-Catenin Pathway in Hepatocellular Carcinoma

et al. 2022

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is regarded as one of the universal cancers in the world. Therefore, our study is based on clinical, molecular mechanism and immunological perspectives to analyze how NAP1L1 affects the progression of HCC. To begin with, the gene expression datasets and clinical data of GSE14520, GSE76427, ICGC, and TCGA are originated from GEO, ICGC, and TCGA databases. Subsequently, DEG screening was performed on data using R studio, and we finally found that 2,145 overlapping DEGs were screened from four datasets at the end. Then, we used R studio to filter the survival-related genes of the GSE76427 and ICGC datasets, and we screened out 101 survival-related genes. Finally, 33 common genes were screened out from 2,145 overlapping DEGs and 101 survival-related genes. Then, NAP1L1 was screened from 33 common genes using the CytoHubba plug-in in Cytoscape software. Furthermore, ground on GEO, ICGC, and TCGA databases, the survival analysis, clinical feature analysis, univariate/multivariate regression analysis, and multiple GSEA were used to study NAP1L1. The Conclusion claimed that HCC patients with higher expression levels of NAP1L1 had a poorer prognosis than those with lower expression levels. Thus, we believe that NAP1L1 is an independent prognostic factor for HCC. In order to shed light on NAP1L1’s molecular mechanism promoting the progression of HCC closely, the GSEA tool was applied to complete the GSEA of the four datasets. Furthermore, the results confirmed that NAP1L1 could promote HCC progression by regulating the G2/M transition of the cell cycle and Wnt signaling pathway. Western blot and flow cytometry were also performed to understand those mechanisms in this study. The result of Western blot showed that NAP1L1 silencing led to downregulation of CDK1 and β-catenin proteins; the result of flow cytometry showed that cell numbers in the G2 phase were significantly increased when NAP1L1 was silenced. Thus, we claimed that NAP1L1 might promote HCC progression by activating the Wnt signaling pathway and promoting cell cycle G2/M transition. In addition, ground on GSE14520 and GSE76427 datasets, and ICGC and TCGA databases, the correlation between NAP1L1 and immune cells was analyzed in HCC patients. At the same time, the TISIDB online database and the TIMER online database were testified to the association between NAP1L1 and immune cells. Hence, the summary shows that NAP1L1 was connected with a certain amount of immune cells. We can speculate that NAP1L1 may influence macrophages to promote HCC progression through some potential mechanisms.

show abstract

“…Expression of NAP1L1 (nucleosome assembly protein 1-like 1) is significantly upregulated in tumor tissues compared with adjacent nontumor tissues in many cancers, including liver, colon, ovarian, breast cancer, etc. [ 57 , 58 , 59 , 60 ]. High NAP1L1 expression in HCC tissues is associated with aggressive clinicopathologic features, such as high serum AFP levels, tumor size, and tumor number.…”

Section: Genes Associated With Doxorubicin Resistancementioning

confidence: 99%

Evaluation and Application of Drug Resistance by Biomarkers in the Clinical Treatment of Liver Cancer

Huang

Wang

et al. 2023

Cells

View full text Add to dashboard Cite

Liver cancer is one of the most lethal cancers in the world, mainly owing to the lack of effective means for early monitoring and treatment. Accordingly, there is considerable research interest in various clinically applicable methods for addressing these unmet needs. At present, the most commonly used biomarker for the early diagnosis of liver cancer is alpha-fetoprotein (AFP), but AFP is sensitive to interference from other factors and cannot really be used as the basis for determining liver cancer. Treatment options in addition to liver surgery (resection, transplantation) include radiation therapy, chemotherapy, and targeted therapy. However, even more expensive targeted drug therapies have a limited impact on the clinical outcome of liver cancer. One of the big reasons is the rapid emergence of drug resistance. Therefore, in addition to finding effective biomarkers for early diagnosis, an important focus of current discussions is on how to effectively adjust and select drug strategies and guidelines for the treatment of liver cancer patients. In this review, we bring this thought process to the drug resistance problem faced by different treatment strategies, approaching it from the perspective of gene expression and molecular biology and the possibility of finding effective solutions.

show abstract

NAP1L1 interacts with hepatoma-derived growth factor to recruit c-Jun inducing breast cancer growth

Cited by 9 publications

References 52 publications

Identification of a chromatin regulator signature and potential candidate drugs for hepatocellular carcinoma

Identification of a chromatin regulator signature and potential candidate drugs for hepatocellular carcinoma

NAP1L1 Functions as a Novel Prognostic Biomarker Associated With Macrophages and Promotes Tumor Progression by Influencing the Wnt/β-Catenin Pathway in Hepatocellular Carcinoma

Evaluation and Application of Drug Resistance by Biomarkers in the Clinical Treatment of Liver Cancer

Contact Info

Product

Resources

About